The Journal of Immunology · 2020 · 41 citations · 28 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-based ImmunotherapyCellular TherapyNatural Killer Cell FunctionT Cell ExhaustionAntitumor Immune ActivationBarriersGlycan-based Cancer TherapeuticsN-glycosylation In CancerNatural Killer Cell Receptor Nkg2dNkg2 Receptor SignalingT Cell Infiltration EnhancementT-cell Therapy
Abstract Adoptive cellular therapy and its derivative, chimeric AgR T cell therapy, have achieved significant progress against cancer. Major barriers persist, however, including insufficient induction of cytotoxic T cells and exhaustion of tumor-infiltrating lymphocytes. In this study, we discovered a new role for 2-deoxy-d-glucose (2DG) in enhancing the antitumor activity of human T cells against NKG2D ligand-expressing tumor cells. Human T cells treated with 2DG upregulated the NK-specific transcription factors TOX2 and EOMES, thereby acquiring NK cell properties, including high levels of perforin/granzyme and increased sensitivity to IL-2. Notably, rather than inhibiting glycolysis, 2DG modified N-glycosylation, which augmented antitumor activity and cell surface retention of IL-2R of T cells. Moreover, 2DG treatment prevented T cells from binding to galectin-3, a potent tumor Ag associated with T cell anergy. Our results, therefore, suggest that modifying N-glycosylation of T cells with 2DG could improve the efficacy of T cell–based immunotherapies against cancer.
28
Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation
Michael Demetriou, Maria Granovsky, Sue Quaggin et al. · Nature · 2001 · 899 citations